Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
The latest announcement is out from Enanta Pharmaceuticals ( (ENTA) ).
Enanta Pharmaceuticals announced promising topline results from their Phase 2 pediatric study of zelicapavir, a novel oral treatment for RSV, showing significant antiviral effects and a favorable safety profile. The study involved children aged 28 days to 36 months and demonstrated a notable reduction in viral load, especially in those treated within three days of symptom onset. These results highlight zelicapavir’s potential as an effective treatment for RSV, supporting further clinical evaluation.
Find detailed analytics on ENTA stock on TipRanks’ Stock Analysis page.
